Findings

What do systematic reviews say?

4,695 questions · 4,979 findings · 433 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%

Intervention not reported

Mean quality of life or "well‐being" · people with cancer pain

1 finding from 1 review

Oral paracetamol (acetaminophen) for cancer pain 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 93 participants
Very low

Intervention not reported

Participant preference · people with cancer pain

1 finding from 1 review

Oral paracetamol (acetaminophen) for cancer pain 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 52 participants
Very low

Intervention not reported

Adverse events · people with cancer pain

1 finding from 1 review

Oral paracetamol (acetaminophen) for cancer pain 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 80 participants
Very low

Intervention not reported

Serious adverse events · people with cancer pain

1 finding from 1 review

Oral paracetamol (acetaminophen) for cancer pain 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 93 participants
Very low

Intervention not reported

Participants with at least 30% or at least 50% reduction in pain · people with cancer pain

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

PGIC much or very much improved · people with cancer pain

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Pain no worse than mild at one or two weeks (or equivalent) · people with cancer pain

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 415 participants
Very low

Intervention not reported

Serious adverse events · people with cancer pain

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 949 participants
Very low

Intervention not reported

Adverse events · people with cancer pain

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Withdrawals · people with cancer pain

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Death · people with cancer pain

1 finding from 1 review

Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 949 participants
Very low

GM-CSF vs placebo or no treatment

Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment

Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
RR 1.10 [0.63, 1.91]
1 study · 36 participants
GRADE not reported

GM-CSF vs placebo or no treatment

Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment

Granulocyte-macrophage colony-stimulating factor (GM-CSF) led to lower number of days of treatment with opioid analgesics compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
MD -1.10 [-1.91, -0.29]
1 study · 90 participants
GRADE not reported

G‐CSF vs placebo or no treatment

Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults with cancer receiving treatment

Granulocyte-colony stimulating factor (G-CSF) showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.16 [0.01, 2.86]
1 study · 40 participants
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
RR 0.89 [0.58, 1.34]
4 studies · 714 participants
GRADE not reported

GM-CSF vs placebo or no treatment

Normalcy of diet (tube feeding) · Adults with cancer receiving treatment

Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (tube feeding) compared with placebo or no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck
RR 0.31 [0.01, 7.09]
1 study · 29 participants
GRADE not reported

Erythropoietin mouthwash vs placebo

Number of days in hospital · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers

Erythropoietin mouthwash showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
MD -2.95 [-7.73, 1.83]
1 study · 80 participants
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days of treatment with opioid analgesics compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
MD -1.41 [-3.33, 0.51]
2 studies · 323 participants
GRADE not reported

Educational intervention with information only (theoretical dental health education, no practical training) vs usual care

Denture-induced stomatitis · Residents of institutions for elderly people (nursing staff and residents took part in the education programme)

1 finding from 1 review

Oral health educational interventions for nursing home staff and residents 2016 · Cochrane All outcomes
Schou 1989 (114 residents, unclear risk of bias): no difference in the prevalence of denture stomatitis between the groups.
1 study · 114 participants
GRADE not reported

Monitoring (any means of observation, supervision, keeping under review, measuring or testing at intervals) vs No monitoring

Quality of life: Chronic pain · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…

The review found no eligible studies for this question.

1 finding from 1 review

Oral health education (advice and training) for people with serious mental illness 2016 · Cochrane All outcomes
No study reported useable data
0 studies
No studies found